SkinHealth Systems Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting a net loss of $888 thousand for the third quarter.
Key Highlights
- Q3 2026 net sales: $69,171 thousand, compared with $70,655 thousand in Q3 2025, according to the filing.
- Q3 2026 net loss: $888 thousand, or $(0.14) per basic and diluted share, versus a net loss of $11,031 thousand in the prior-year quarter.
- Nine-month net loss: $10,187 thousand for the nine months ended September 30, 2026, compared with $1,415 thousand for the same period in 2025.
- Cash position: Cash, cash equivalents, and restricted cash declined to $112,386 thousand at September 30, 2026 from $232,673 thousand at December 31, 2025.
- Total assets: $389,061 thousand at September 30, 2026, down from $499,803 thousand at December 31, 2025.
- Shares outstanding: 6,542,468 shares of Class A Common Stock as of November 2, 2026, the filing stated.
- Accumulated deficit: $(527,671) thousand at September 30, 2026, compared with $(517,484) thousand at December 31, 2025.
SkinHealth Systems Q3 2026 Financial Results and Balance Sheet Position
According to the filing, SkinHealth Systems Inc. (NASDAQ:SKIN) reported net sales of $69,171 thousand for the three months ended September 30, 2026, a decrease from $69,655 thousand in the same period of 2025. Gross profit for Q3 2026 was $47,147 thousand, compared with $45,634 thousand a year earlier. Total operating expenses declined to $42,169 thousand from $51,876 thousand in Q3 2025, resulting in income from operations of $4,978 thousand for the quarter, versus a loss from operations of $6,242 thousand in Q3 2025.
The company disclosed interest expense of $6,271 thousand for the three months ended September 30, 2026. After accounting for interest income of $1,394 thousand and other items, the registrant reported a net loss of $888 thousand for Q3 2026, or $(0.14) per basic and diluted share. For the nine months ended September 30, 2026, net sales were $206,194 thousand and the net loss totaled $10,187 thousand, or $(1.58) per basic and diluted share.
On the balance sheet, total liabilities decreased to $333,305 thousand at September 30, 2026 from $438,747 thousand at December 31, 2025, primarily reflecting the removal of $123,959 thousand in current convertible senior notes that appeared at year-end 2025. Convertible senior notes, net, were reported at $242,964 thousand under long-term liabilities at September 30, 2026. Total stockholders' equity was $55,756 thousand at the close of the quarter. The registrant is classified as an accelerated filer and is incorporated in Delaware, with principal executive offices in Long Beach, California.
What Was Disclosed
SkinHealth Systems filed its quarterly report for the period ended September 30, 2026, disclosing a Q3 net loss of $888 thousand on net sales of $69,171 thousand, a reduced cash balance of $112,386 thousand, and total assets of $389,061 thousand.




Please wait processing your request...